#United States #New York #Wolf Haldenstein #SEC Claims #Curanex Pharmaceuticals

Investigation of Curanex Pharmaceuticals

Wolf Haldenstein Adler Freeman & Herz LLP has initiated an investigation responding to possible securities fraud claims concerning Curanex Pharmaceuticals Inc. (NASDAQ: CURX). This inquiry aims to scrutinize whether the company and its higher-ups have committed any violations in relation to securities regulations.

Background on Curanex Pharmaceuticals

Curanex Pharmaceuticals operates as a developmental stage pharmaceutical company, focusing on the discovery, development, and commercialization of botanical drugs targeted towards patients suffering from various immune and inflammatory diseases. The company made its Initial Public Offering (IPO) on August 26, 2025, offering 3.75 million shares at $4.00 each and garnering significant gross proceeds of $15 million. The IPO was led by Dominari Securities, which later exercised an overallotment option, bringing in additional shares.

In the immediate aftermath of the IPO, Curanex saw a substantial rise in its share price alongside heightened trading volumes. The stock reached its apex on September 16, 2025, closing at an impressive $9.16. However, the situation rapidly deteriorated; by September 17, 2025, trading was halted due to volatility, with shares plummeting to $1.51 by the close of trading – a stark decline following an extraordinary volume of 26 million shares.

The Investigation

Wolf Haldenstein's inquiry comes in light of sharp fluctuations in Curanex's stock and aims to ascertain whether the company, alongside directors or officers, engaged in activities that could be construed as securities fraud or any other illicit business practices. Investors who acquired shares of Curanex and subsequently endured losses are encouraged to come forward.

Gregory Stone, a contact within the firm, urges any impacted shareholders to reach out via telephone at (800) 575-0735 or (212) 545-4774, or through email at [email protected]. Additionally, interested parties may fill out a contact form provided on the firm’s website.

Legal Support from Wolf Haldenstein

Renowned for its expertise, Wolf Haldenstein Adler Freeman & Herz LLP has a solid track record of managing securities class actions and derivative litigation across various courts in the United States. The firm maintains a strong presence with offices in notable cities such as New York, Chicago, Nashville, and San Diego.

The reputation of Wolf Haldenstein for representing shareholder interests has been significantly acknowledged in previous cases, with courts often appointing the firm to take lead roles in complex securities litigation matters.

If you possess any queries pertaining to this investigation or wish to discuss your potential claims, you are urged to contact Wolf Haldenstein directly at the provided phone numbers or email addresses. For more details, please visit www.whafh.com.

Conclusion

The attention this investigation has drawn underlines a crucial area of concern for shareholders of Curanex Pharmaceuticals. The outcome may hold significant implications not only for the company but for all stakeholders involved. Shareholders are advised to remain vigilant and proactive as this situation develops.